Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
1. Substance P (6-11), Succinyl-asp(6)-me-phe(8)-
2. Substance P (6-11), Succinyl-aspartyl(6)-methylphenylalanine(8)-
3. Succinyl-6-asp-8-me-phe-substance P (6-11)
1. 106128-89-6
2. Chembl106124
3. (5s,8s,14s,17s,20s)-14,17-dibenzyl-5-carbamoyl-20-(carboxymethyl)-8-isobutyl-15-methyl-7,10,13,16,19,22-hexaoxo-2-thia-6,9,12,15,18,21-hexaazapentacosan-25-oic Acid
4. Succinyl-6-asp-8-me-phe-substance P (6-11)
5. Substance P (6-11), Succinyl-asp(6)-me-phe(8)-
6. Substance P (6-11), Succinyl-aspartyl(6)-methylphenylalanine(8)-
7. Gtpl2127
8. Schembl5238634
9. Dtxsid80909926
10. Suc[asp6,mephe3]sp(6-11)
11. Hy-p0187
12. Suc[asp6,mephe3]sp(6-11))
13. Bdbm50052524
14. Mfcd00076799
15. Zinc95615286
16. Cs-8091
17. (3s)-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[(4-hydroxy-4-oxobutanoyl)amino]-4-oxobutanoic Acid
18. 4-10-neuromedin B (swine Spinal Cord), N-(3-carboxy-1-oxopropyl)-6-(n-methyl-l-phenylalanine)-7-de-l-valine-
19. L-methioninamide, N-(3-carboxy-1-oxopropyl)-l-alpha-aspartyl-l-phenylalanyl-n-methyl-l-phenylalanylglycyl-l-leucyl-
20. N-(3-carboxy-1-oxopropyl)-6-(n-methyl-l-phenylalanine)-7-de-l-valine-4-10-neuromedin B (swine Spinal Cord)
21. B6580
22. A16945
23. Succinyl-(asp6,n-me-phe8)-substance P (6-11)
24. J-001543
25. Q27088780
26. (3s)-4-[[(2s)-1-[[(2s)-1-[[2-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(3-carboxypropanoylamino)-4-oxobutanoic Acid
27. (s)-n-((s)-1-{[(s)-1-({[(s)-1-((s)-1-carbamoyl-3-methylsulfanyl-propylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-carbamoyl)-2-phenyl-ethyl]-methyl-carbamoyl}-2-phenyl-ethyl)-3-(3-carboxy-propionylamino)-succinamic Acid
28. 4-({14-benzyl-7,10,13-trihydroxy-5-[hydroxy(imino)methyl]-15-methyl-8-(2-methylpropyl)-16-oxo-18-phenyl-2-thia-6,9,12,15-tetraazaoctadeca-6,9,12-trien-17-yl}imino)-3-[(3-carboxy-1-hydroxypropylidene)amino]-4-hydroxybutanoic Acid
Molecular Weight | 842.0 g/mol |
---|---|
Molecular Formula | C40H55N7O11S |
XLogP3 | 1.1 |
Hydrogen Bond Donor Count | 8 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 26 |
Exact Mass | 841.36802677 g/mol |
Monoisotopic Mass | 841.36802677 g/mol |
Topological Polar Surface Area | 309 Ų |
Heavy Atom Count | 59 |
Formal Charge | 0 |
Complexity | 1450 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Global Sales Information
Market Place
ABOUT THIS PAGE
A Natalizumab manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Natalizumab, including repackagers and relabelers. The FDA regulates Natalizumab manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Natalizumab API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Natalizumab manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Natalizumab supplier is an individual or a company that provides Natalizumab active pharmaceutical ingredient (API) or Natalizumab finished formulations upon request. The Natalizumab suppliers may include Natalizumab API manufacturers, exporters, distributors and traders.
click here to find a list of Natalizumab suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Natalizumab Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Natalizumab GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Natalizumab GMP manufacturer or Natalizumab GMP API supplier for your needs.
A Natalizumab CoA (Certificate of Analysis) is a formal document that attests to Natalizumab's compliance with Natalizumab specifications and serves as a tool for batch-level quality control.
Natalizumab CoA mostly includes findings from lab analyses of a specific batch. For each Natalizumab CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Natalizumab may be tested according to a variety of international standards, such as European Pharmacopoeia (Natalizumab EP), Natalizumab JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Natalizumab USP).
LOOKING FOR A SUPPLIER?